Enzyme by Design Information

Enzyme by Design (EbD) is a preclinical stage startup focused on designing and developing oncology biologics that are highly effective at exploiting weaknesses in cancers and eradicating tumor cells but with a clear focus on patient safety and reducing side effects. In this way, we can both treat the disease and improve patient quality of life and outcomes. We have used our core expertise of protein engineering to create protein molecules that target the most common pediatric cancer as well as infamously difficult to treat cancers like acute myeloid leukemia and the solid tumors pancreatic, liver, and ovarian cancers. Utilizing well-known drug mechanisms of action and patient genomic and epigenetic markers will guide our clinical strategy as we move forward to make sure that only patients likely to benefit greatly from our biologics will be receiving them. The time is now for better cancer treatment options.